Bediol Strain

Genetics & Lineage

Parentage not published by the breeder. No single parent pair is established for this catalog entry. Areto does not estimate parents it has no report of.

Effects

Aroma & Taste

Academic research (26 studies)

Peer-reviewed, open-access studies that examined samples sold or grown under this name. Findings describe those samples, not the breeder’s release, and may not match every product. Each quote is copied from the paper’s full text.

• Cannabinoids: The paper states that Bediol contains 6.5% THC and 8% CBD, in contrast to the high-THC Bedrocan.

  “Bedrocan’s constituents are 22% THC and <1% CBD, while Bediol contains 6.5% THC and 8% CBD and Bedrolite contains 9% CBD and 0.4% THC”

  Fanelli G et al. (2017). Cannabis and intractable chronic pain: an explorative retrospective analysis of Italian cohort of 614 patients. Journal of pain research. doi:10.2147/jpr.s132814

• Cannabinoids: The study used Bediol cannabis containing 6% THC and 7.5% CBD, loaded to deliver 8 mg THC plus 10 mg CBD (Cann+CBD).

  “Bediol (6% THC, 7.5% CBD), and placebo cannabis were used to load doses of 8 mg THC + 10 mg CBD (Cann+CBD)”

  Freeman TP et al. (2018). Cannabis Dampens the Effects of Music in Brain Regions Sensitive to Reward and Emotion. The international journal of neuropsychopharmacology. doi:10.1093/ijnp/pyx082

• Cannabinoids: The paper reports the Bediol variety as containing 6.3% THC and 8% CBD, a combined THC/CBD chemotype.

  “The Bediol cannabis variety is characterized by the combination of 6.3% THC (63 mg per gram) and 8% CBD (80 mg per gram).”

  van de Donk T et al. (2019). An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. Pain. doi:10.1097/j.pain.0000000000001464

• Cannabinoids: The paper lists Bediol as a C. sativa product with 6.5% Δ9-THC and 8% CBD.

  “Bediol | C. sativa | 6.5 | 8 | Anti‐anxiety effect, insomnia treatment, anti‐inflammatory effect | 57, 58”

  Palmieri B, Laurino C, Vadalà M. (2019). Spontaneous, anecdotal, retrospective, open-label study on the efficacy, safety and tolerability of cannabis galenical preparation (Bedrocan). The International journal of pharmacy practice. doi:10.1111/ijpp.12514

• Cannabinoids: The paper classes Bediol as chemotype II, with oils containing both THC and CBD.
  chemotype IITHCCBD

  “principally contain THC (chemotype I: Bedrocan) or CBD (chemotype III: Bedrolite) or both of them (chemotype II: FM2 and Bediol)”

  Dei Cas M et al. (2020). Phytocannabinoids Profile in Medicinal Cannabis Oils: The Impact of Plant Varieties and Preparation Methods. Frontiers in pharmacology. doi:10.3389/fphar.2020.570616

• Cannabinoids: In trichome extracts of four C. sativa varieties including Bediol, the paper reports Δ9-THC, THCA, CBD, CBDA and CBCA were identified; results are not given per variety.
  Δ9-THCTHCACBDCBDACBCA

  “C. sativa varieties Bediol, Bedica, Bedrobinol, and Bedrocan, during the last 4 weeks of their flowering (Happyana and Kayser, 2013). In the chloroform extracts, the cannabinoids Δ9-THC, THCA, CBD, CBDA, and CBCA were identified”

  Aliferis KA, Bernard-Perron D. (2020). Cannabinomics: Application of Metabolomics in Cannabis (Cannabis sativa L.) Research and Development. Frontiers in plant science. doi:10.3389/fpls.2020.00554

• Cannabinoids: The paper's variety table lists Bediol with approximately 6.3% THC and approximately 8% CBD, from the Netherlands.

  “Bedrocan Inernational® | Bediol® | ≅6.3 | ≅8 | Netherlands”

  Brunetti P et al. (2020). Herbal Preparations of Medical Cannabis: A Vademecum for Prescribing Doctors. Medicina (Kaunas, Lithuania). doi:10.3390/medicina56050237

• Cannabinoids: The paper states Bediol granolate contains approximately 6.3% THC and 8% CBD.

  “The Bediol® granolate contains approximately 6.3% THC and 8% CBD.”

  Salami SA et al. (2020). It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets. Molecules (Basel, Switzerland). doi:10.3390/molecules25184036

• Cannabinoids: The paper reports Bediol as containing 13.4 mg Δ9-THC and 17.8 mg CBD in a study of CBD- and THC-containing drugs.

  “Bediol 13.4 mg Δ9-THC + 17.8 mg CBD”

  Mlost J, Bryk M, Starowicz K. (2020). Cannabidiol for Pain Treatment: Focus on Pharmacology and Mechanism of Action. International journal of molecular sciences. doi:10.3390/ijms21228870

• Cannabinoids: The paper reports Bediol as a cannabis variety containing 13.4 mg THC and 17.8 mg CBD.

  “Bediol (13.4 mg THC, 17.8 mg CBD), and Bedrolite (18.4 mg CBD, <1 mg THC)”

  Khurshid H et al. (2021). A Systematic Review of Fibromyalgia and Recent Advancements in Treatment: Is Medicinal Cannabis a New Hope? Cureus. doi:10.7759/cureus.17332

• Cannabinoids: The paper reports Bediol herbal cannabis as containing 6.3% THC and 8% CBD.
  THC 6.3%CBD 8%

  “As concerns the available herbal Cannabis species, Bediol® (THC 6.3%; CBD 8%) is usually recommended as the first-choice therapy to alleviate pain or as an anti-inflammatory therapy.”

  Baratta F et al. (2022). Cannabis for Medical Use: Analysis of Recent Clinical Trials in View of Current Legislation. Frontiers in pharmacology. doi:10.3389/fphar.2022.888903

• Cannabinoids: Bediol was reported at 13.4 mg THC and 17.8 mg CBD (roughly 1:1 THC:CBD) in a fibromyalgia trial summarized by the paper.

  “Bediol 13.4 mg THC: 17.8 mg CBD VS Bedrolite <1 mg THC: 18.4 mg CBD”

  Seifalian A, Kenyon J, Khullar V. (2022). Dysmenorrhoea: Can Medicinal Cannabis Bring New Hope for a Collective Group of Women Suffering in Pain, Globally? International journal of molecular sciences. doi:10.3390/ijms232416201

• Cannabinoids: The paper describes the Bediol inhaled cannabis used in the trial as containing 6.3% THC and 8% CBD.

  “inhaled cannabis (Bediol®, containing 6.3% Δ9-tetrahydrocannabinol and 8% cannabidiol)”

  van Dam CJ et al. (2023). Cannabis-opioid interaction in the treatment of fibromyalgia pain: an open-label, proof of concept study with randomization between treatment groups: cannabis, oxycodone or cannabis/oxycodone combination-the SPIRAL study. Trials. doi:10.1186/s13063-023-07078-6

• Cannabinoids: Non-targeted LC-HRMS/MS of Bediol flowers reported CBD, CBDA, THC, THCA, CBGA and CBN.
  CBDCBDATHCTHCACBGACBN

  “LC-HRMS/MS | Flowers | Bediol | Analyzed using a non-targeted metabolomics approach. Isocratic elution with water/MeCN 30:70 and 0.1% formic acid. | CBD, CBDA, THC, THCA, CBGA, and CBN | [29]”

  Jadhav PD et al. (2023). A Metabolomics and Big Data Approach to Cannabis Authenticity (Authentomics). International journal of molecular sciences. doi:10.3390/ijms24098202

• Cannabinoids: The paper reports the Bediol variety used in the study contained 13.4 mg THC and 17.8 mg CBD.

  “Bediol* (13.4 mg THC, 17.8 mg CBD)”

  Paland N et al. (2023). Cannabis and Rheumatoid Arthritis: A Scoping Review Evaluating the Benefits, Risks, and Future Research Directions. Rambam Maimonides medical journal. doi:10.5041/rmmj.10509

• Cannabinoids: The paper lists Bediol as a granulate standardised to 6.3% THC and 8.0% CBD.

  “Bediol | Standardised on 6.3% | Standardised on 8.0% | Inexperienced (with cannabis) patient. Pain, with and without spasm, in patients with MS. Other pathologies with spasms and abnormal muscle activity. | Granulate | [46,48]”

  Woerdenbag HJ et al. (2023). Potential, Limitations and Risks of Cannabis-Derived Products in Cancer Treatment. Cancers. doi:10.3390/cancers15072119

• Cannabinoids: The study used Bediol inhaled cannabis containing 6.3% THC (9.5 mg) and 8% CBD (12 mg) per 150 mg dose.

  “150 mg of inhaled cannabis (Bediol, Bedrocan International BV, The Netherlands) containing 6.3% THC (9.5 mg) and 8% CBD (12 mg)”

  van Dam CJ et al. (2024). Cannabis combined with oxycodone for pain relief in fibromyalgia pain: a randomized clinical self-titration trial with focus on adverse events. Frontiers in pain research (Lausanne, Switzerland). doi:10.3389/fpain.2024.1497111

• Cannabinoids: Bediol is described as a low-THC balanced strain with a THC:CBD ratio of 6:7.5.
  THC:CBD 6:7.5

  “the low THC balanced strain Bediol (THC:CBD=6:7.5) in 24.5%”

  Szejko N et al. (2024). Medicinal Use of Different Cannabis Strains: Results from a Large Prospective Survey in Germany. Pharmacopsychiatry. doi:10.1055/a-2261-2269

• Cannabinoids: The paper states that Bediol, a Dutch medical cannabis type, has a balanced ratio of 6% THC and 8% CBD.

  “For instance, Bediol, which has a balanced ratio of 6 % THC and 8 % CBD, is frequently recommended as an initial treatment for chronic nerve pain.”

  Hossain MK, Chae HJ. (2024). Medical cannabis: From research breakthroughs to shifting public perceptions and ensuring safe use. Integrative medicine research. doi:10.1016/j.imr.2024.101094

• Cannabinoids: A case report states the Bediol product prescribed to an ADHD patient contained THC 6.3% and CBD 8%.
  THC 6.3%CBD 8%

  “Bedrocan® (THC 20%; CBD 0.5%) and Bediol® (THC 6.3%; CBD 8%) were prescribed.”

  Dallabrida KG et al. (2024). Endocannabinoid System Changes throughout Life: Implications and Therapeutic Potential for Autism, ADHD, and Alzheimer's Disease. Brain sciences. doi:10.3390/brainsci14060592

• Cannabinoids: The paper reports Bediol flowers contained 6.3% THC (63 mg/g) and 8% CBD (80 mg/g).

  “Bediol – 6.3% THC (63 mg/g), 8% CBD (80 mg/g)”

  Perez JG et al. (2025). Cannabinoids for Anxiety and Sleep Disturbances: A Scoping Review. Medical cannabis and cannabinoids. doi:10.1159/000548890

• Cannabinoids: The paper lists Bediol as a standardized inflorescence product with THC 6.3% and CBD 8%.
  THC 6.3%CBD 8%

  “Bediol® (THC 6.3%, CBD 8%)”

  Caicedo DA et al. (2025). An Overview of the Potential for Pharmacokinetic Interactions Between Drugs and Cannabis Products in Humans. Pharmaceutics. doi:10.3390/pharmaceutics17030319

• Cannabinoids: The paper states Bediol flower was used with standardized THC and CBD levels of 6.5% and 8%, respectively; these are stated standardized values, not measured results.

  “Bediol® (THC and CBD levels standardized at concentrations of 6.5% and 8%, respectively)”

  Manca A et al. (2025). &lt;i&gt;COMT&lt;/i&gt; Genetic Variants and BDNF Level Associations with Cannabinoid Plasma Exposure: A Preliminary Study. Journal of xenobiotics. doi:10.3390/jox15030066

• Cannabinoids: The cited trial reported the Bediol formulation contained 13.4 mg THC and 17.8 mg CBD.

  “Bediol (13.4 mg THC, 17.8 mg CBD), increased the pressure pain threshold and caused euphoria as measured by the Bowdle questionnaire.”

  Varadpande M et al. (2026). UK Medical Cannabis Registry: a case series analysing clinical outcomes of medicinal cannabis therapy for fibromyalgia. Clinical rheumatology. doi:10.1007/s10067-025-07846-6

• Terpenes: Myrcene content was not clearly reduced by irradiation in Bediol, unlike in Bedica and Bedrolite.
  myrcene

  “myrcene content was clearly reduced in varieties Bedica and Bedrolite but not in variety Bediol.”

  Hazekamp A. (2016). Evaluating the Effects of Gamma-Irradiation for Decontamination of Medicinal Cannabis. Frontiers in pharmacology. doi:10.3389/fphar.2016.00108

• Terpenes: The paper cites a literature value of about 64,000 mg/kg total terpenes for Bediol®, lower than the paper's own inflorescences (~91,325 mg/kg).

  “while higher than that observed in Bediol® (~64,000 mg/kg) [29]”

  Boffa L, Binello A, Cravotto G. (2024). Efficient Capture of Cannabis Terpenes in Olive Oil during Microwave-Assisted Cannabinoid Decarboxylation. Molecules (Basel, Switzerland). doi:10.3390/molecules29040899

Areto Research estimateNot published by the breeder. Areto Research estimated this from the strain’s name, reported parentage and commonly described traits; it is not a source, a lab result or a prediction for any product. Details marked “general guess” have low confidence. Each estimate is replaced as soon as a breeder publishes that detail.

Indica, sativa and hybrid are retail shopping labels, not genetics. Parentage is breeder-reported and not DNA-verified. Use your product’s batch COA for tested potency. How Areto sources this page.